# Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

> **NCT03546907** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 343 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** SAR440340
- **DRUG:** Placebo
- **DRUG:** Any Inhaled Corticosteroids as prescribed by treating physician as standard of care
- **DRUG:** Any Long Acting Beta Agonist as prescribed by treating physician as standard of care
- **DRUG:** Any Long Acting Muscarinic Agonist as prescribed by treating physician as standard of care
- **DRUG:** Any short-acting β agonist as prescribed by treating physician as standard of care

## Key facts

- **NCT ID:** NCT03546907
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-16
- **Primary completion:** 2019-10-03
- **Final completion:** 2020-02-21
- **Target enrollment:** 343 (ACTUAL)
- **Last updated:** 2022-11-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03546907

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03546907, "Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03546907. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*